HDAC2 as a new target to improve schizophrenia treatment
- 9 January 2013
- journal article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 13 (1) , 1-3
Abstract
One of the main characteristics of treatment of psychiatric disorders, such as schizophrenia and depression, is the chronic administration (weeks, months or even years) of therapeutic compounds. A ...Keywords
This publication has 20 references indexed in Scilit:
- Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic DrugsCell, 2011
- A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic PatientsThe Journal of Clinical Psychiatry, 2011
- Schizophrenia: The making of a troubled mindNature, 2010
- Augmentation of atypical antipsychotics with valproic acid. An open‐label study for most difficult patients with schizophreniaHuman Psychopharmacology: Clinical and Experimental, 2009
- Group II metabotropic glutamate receptors and schizophreniaCellular and Molecular Life Sciences, 2009
- Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of SchizophreniaNeuropsychopharmacology, 2008
- Decoding the Epigenetic Language of Neuronal PlasticityNeuron, 2008
- Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylationProceedings of the National Academy of Sciences, 2008
- Serotonin research: contributions to understanding psychosesTrends in Pharmacological Sciences, 2008
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008